The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 701–800 of 1,025
Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders
Yuan, A., & Nixon, R. A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.09.002 · Cited by 88
Free radical theory of aging: Alzheimer’s disease pathogenesis
Harman, D. (1995) · AGE · doi:10.1007/bf02436085 · Cited by 87
Götz, J., Xia, D., Leinenga, G., Chew, Y. L., & Nicholas, H. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00072 · Cited by 91
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Zhou, Q., Li, S., Li, M., Ke, D., Wang, Q., Yang, Y., Liu, G., Wang, X., Liu, E., & Wang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103970 · Cited by 92
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113
Esteves-Villanueva, J. O., Trzeciakiewicz, H., & Martić, S. (2014) · The Analyst · doi:10.1039/c4an00204k · Cited by 87
Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD
Wolk, D. A., Mancuso, L., Kliot, D., Arnold, S. E., & Dickerson, B. C. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.02.014 · Cited by 84
Reduction of O-LinkedN-Acetylglucosamine-Modified Assembly Protein-3 in Alzheimer’s Disease
Yao, P. J., & Coleman, P. D. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02399.1998 · Cited by 85
Iron Deposition Leads to Hyperphosphorylation of Tau and Disruption of Insulin Signaling
Wan, W., Cao, L., Kalionis, B., Murthi, P., Xia, S., & Guan, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00607 · Cited by 84
Moore, K. B. E., Hung, T.-J., & Fortin, J. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103487 · Cited by 93
Chen, S., Li, B., Grundke, I., & Iqbal, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709852200 · Cited by 84
Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors
Okuda, M., Hijikuro, I., Fujita, Y., Teruya, T., Kawakami, H., Takahashi, T., & Sugimoto, H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.092 · Cited by 85
Holzer, M., Holzapfel, H.-P., Zedlick, D., Brückner, M. K., & Arendt, T. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90546-0 · Cited by 83
In Vivo Reversal of Amyloid-β Lesions in Rat Brain
Sigurdsson, E. M., Permanne, B., Soto, C. A., Wısnıewskı, T., & Frangione, B. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.11 · Cited by 83
Luchena, C., Zuazo-Ibarra, J., Alberdi, E. M., Matute, C., & Capetillo‐Zarate, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/2530414 · Cited by 84
Rhodanine and Thiohydantoin Derivatives for Detecting Tau Pathology in Alzheimer’s Brains
Ono, M., Hayashi, S., Matsumura, K., Kimura, H., Okamoto, Y., Ihara, M., Takahashi, R., Mori, H., & Saji, H. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200002t · Cited by 83
Amyloid load in nondemented brains correlates with APOE e4
Caselli, R. J., Walker, D. G., Sue, L. I., Sabbagh, M. N., & Beach, T. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.016 · Cited by 85
Buscema, M., Grossi, E., Snowdon, D. A., & Antuono, P. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908928 · Cited by 82
Individual Growth Curve Analysis of APOE ε4–Associated Cognitive Decline in Alzheimer Disease
Hoyt, B. D., Massman, P. J., Schatschneider, C. W., Cooke, N., & Doody, R. S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.454 · Cited by 83
Kobro‐Flatmoen, A., Nagelhus, A., & Witter, M. P. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.012 · Cited by 78
The Dynamics and Turnover of Tau Aggregates in Cultured Cells
Guo, J., Buist, A., Soares, A. C., Callaerts, K., Calafate, S., Stevenaert, F., Daniels, J. P., Zoll, B. E., Crowe, A., Brunden, K. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712083 · Cited by 83
Denver, P., & McClean, P. L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238608 · Cited by 89
Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients
Hellström‐Lindahl, E., Mousavi, M. T., Ravid, R., & Nordberg, A. K. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.11.024 · Cited by 83
Quantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease
Scheff, S. W., Sparks, D. L., & PRICE, D. A. (1993) · Annals of Neurology · doi:10.1002/ana.410340309 · Cited by 83
Shimada, H., Kitamura, S., Shinotoh, H., Endo, H., Niwa, F., Hirano, S., Kimura, Y., Zhang, M., Kuwabara, S., Suhara, T., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.009 · Cited by 83
Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90
An okadaic acid-induced model of tauopathy and cognitive deficiency
Zhang, Z., & Simpkins, J. W. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.077 · Cited by 82
Dai, J., Buijs, R. M., Kamphorst, W., & Swaab, D. F. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03152-9 · Cited by 81
Is Huntington's disease a tauopathy?
Gratuze, M., Cisbani, G., Cicchetti, F., & Planel, E. (2016) · Brain · doi:10.1093/brain/aww021 · Cited by 81
Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex
Welikovitch, L. A., Carmo, S. D., Maglóczky, Z., Szocsics, P., Lőke, J., Freund, T. F., & Cuello, A. C. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1922-z · Cited by 84
A possible link between astrocyte activation and tau nitration in Alzheimer's disease
Reyes, J. F., Reynolds, M. R., Horowitz, P. M., Fu, Y., Guillozet-Bongaarts, A. L., Berry, R., & Binder, L. I. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.005 · Cited by 85
Dyrk1A Inhibition as Potential Treatment for Alzheimer’S Disease
Stotani, S., Giordanetto, F., & Medda, F. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0013 · Cited by 78
Apolipoprotein E genotype and Lewy body disease
Lippa, C. F., Smith, T. W., Saunders, A. M., Crook, R., Pulaski-Salo, D., Davies, P., Hardy, J., Roses, A. D., & Dickson, D. W. (1995) · Neurology · doi:10.1212/wnl.45.1.97 · Cited by 80
Transcriptional and conformational changes of the tau molecule in Alzheimer's disease
Hyman, B. T., Augustinack, J. C., & Ingelsson, M. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.015 · Cited by 79
Self-citationCan exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79
Sabbagh, M. N., Cooper, K., DeLange, J., Stoehr, J. D., Thind, K., Lahti, T., Reisberg, B., Sue, L., Vedders, L., Fleming, S. R., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162340 · Cited by 79
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79
Shioi, J., Georgakopoulos, A., Mehta, P. D., Kouchi, Z., Litterst, C. M., Baki, L., & Robakis, N. K. R. K. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04391.x · Cited by 80
Metals in alzheimer's disease: a systemic perspective
Squitti, R. (2011) · Frontiers in bioscience · doi:10.2741/3938 · Cited by 80
TDP-43 suppresses tau expression via promoting its mRNA instability
Gu, J., Wu, F., Xu, W., Shi, J., Hu, W. H., Jin, N., Qian, W., Wang, X., Iqbal, K., Gong, C., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx175 · Cited by 80
DNA methylation alterations in Alzheimer’s disease
Yokoyama, A. S., Rutledge, J. C., & Medici, V. (2017) · Current Zoology · doi:10.1093/eep/dvx008 · Cited by 84
Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Singh, A. K., Singh, S. K., Nandi, M. K., Mishra, G., Maurya, A., Rai, A., Rai, G. K., Awasthi, R., Sharma, B., & Kulkarni, G. T. (2019) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524919666190820160053 · Cited by 79
The therapeutic landscape of tauopathies: challenges and prospects
Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo, L. M., & Harris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01321-7 · Cited by 85
Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction—the trigger for PANoptosis in neurons
Meng, X., Song, Q., Liu, Z., Liu, X., Wang, Y., & Liu, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1400544 · Cited by 84
Iqbal, K., Alonso, A. D. C., & Grundke, I. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14402 · Cited by 77
Giannakopoulos, P., Silhol, S., Jallageas, V., Mallet, J. J., Bons, N., Bouras, C., & Delaère, P. (1997) · Acta Neuropathologica · doi:10.1007/s004010050684 · Cited by 78
MRI of human entorhinal cortex: a reliable protocol for volumetric measurement
Goncharova, I. I., Dickerson, B. C., Stoub, T. R., & deToledo‐Morrell, L. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00270-6 · Cited by 80
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.027 · Cited by 80
Sigurdsson, E. M., Lee, J. M., Dong, X.-W., Hejna, M. J., & Lorens, S. A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00154-1 · Cited by 81
Hashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78
Friedberg, J. S., Aytan, N., Cherry, J. D., Xia, W., Standring, O. J., Alvarez, V. E., Nicks, R., Svirsky, S. E., Meng, G., Jun, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59869-5 · Cited by 82
Largo‐Barrientos, P., Apóstolo, N., Creemers, E., Callaerts‐Vegh, Z., Swerts, J., Davies, C., McInnes, J., Wierda, K. D. B., Strooper, B. D., Spires‐Jones, T. L., et al. (2021) · Neuron · doi:10.1016/j.neuron.2020.12.016 · Cited by 80
Anatomy of the medial temporal lobe
Hoesen, G. W. V. (1995) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(95)02012-i · Cited by 82
Gong, C., Liu, F., Grundke, I., & Iqbal, K. (2006) · BioMed Research International · doi:10.1155/jbb/2006/31825 · Cited by 81
Didic, M., Félician, O., Barbeau, E. J., Mancini, J., Latger-Florence, C., Tramoni, E., & Ceccaldi, M. P. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000347203 · Cited by 88
Giannakopoulos, P., Hof, P. R., Giannakopoulos, A.-S., Herrmann, F. R., Michel, J.-P., & Bouras, C. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540360028012 · Cited by 78
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N. N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds355 · Cited by 78
Olfactory dysfunction in the pathophysiological continuum of dementia
Bathini, P., Brai, E., & Auber, L. A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100956 · Cited by 77
Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment
Mitchell, T. W., Nissanov, J., Han, L.-Y., Mufson, E. J., Schneider, J. A., Cochran, E. J., Bennett, D. A., Lee, V. M.-Y., Trojanowski, J. Q., & Arnold, S. E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801206 · Cited by 78
Persistent repression of tau in the brain using engineered zinc finger protein transcription factors
Wegmann, S., DeVos, S. L., Zeitler, B., Marlen, K., Bennett, R. E., Perez-Rando, M., MacKenzie, D., Yu, Q., Commins, C., Bannon, R. N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1611 · Cited by 77
Self-citationCheng, L. L., Newell, K., Mallory, A. E., Hyman, B. T., & Gonzalez, R. G. (2002) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(02)00512-x · Cited by 77
Self-citationIshiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77
Luengo, E., Buendía, I., Fernández‐Mendívil, C., Trigo-Alonso, P., Negredo, P., Michalska, P., Hernández-García, B. J., Sánchez‐Ramos, C., Bernal, J. A., Ikezu, T., et al. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12578 · Cited by 76
Shimojo, M., Takuwa, H., Takado, Y., Tokunaga, M., Tsukamoto, S., Minatohara, K., Ono, M., Seki, C., Maeda, J., Urushihata, T., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2880-19.2020 · Cited by 81
Rodriguez, G. A., Barrett, G., Duff, K., & Hussaini, S. A. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000851 · Cited by 78
The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model
Yuste‐Checa, P., Trinkaus, V. A., Riera-Tur, I., Imamoglu, R., Schaller, T., Wang, H., Dudanova, I., Hipp, M. S., Bracher, A., & Hartl, F. U. (2021) · Nature Communications · doi:10.1038/s41467-021-25060-1 · Cited by 78
Bryant, A. G., Li, Z., Jayakumar, R., Serrano‐Pozo, A., Woost, B., Hu, M., Woodbury, M. E., Wachter, A., Lin, G., Kwon, T., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0237-23.2023 · Cited by 84
Self-citationAbsence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia
Falke, E., Han, L.-Y., & Arnold, S. E. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00104-9 · Cited by 77
Hydrogen peroxide can be generated by tau in the presence of Cu(II)
Su, X., Wu, W., Huang, Z., Hu, J. N., Lei, P., Yu, C., Zhao, Y., & Li, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.191 · Cited by 77
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy
Quraishe, S., Cowan, C. M., & Mudher, A. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.32 · Cited by 76
Yanovsky, I., Finkin-Groner, E., Zaikin, A., Lerman, L., Shalom, H., Zeeli, S., Weill, T., Ginsburg, I., Nudelman, A., & Weinstock, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301411g · Cited by 77
Yu, L., Wang, W., Pang, W., Xiao, Z.-H., Jiang, Y., & Hong, Y. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161216 · Cited by 77
Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B. R., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 79
Hall, G. F., Chu, B., Lee, G. S., & Yao, J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.8.1373 · Cited by 78
Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease
Iqbal, K., Gong, C., & Liu, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.870156 · Cited by 76
TOC1: Characterization of a Selective Oligomeric Tau Antibody
Ward, S., Himmelstein, D. S., Lancia, J. K., Fu, Y., Patterson, K. R., & Binder, L. I. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131235 · Cited by 81
Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 82
Hyman, B. T., & Gómez‐Isla, T. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90031-0 · Cited by 74
Self-citationAstrocytic propagation of Tau in the context of Alzheimer's disease
Fleeman, R. M., & Proctor, E. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.645233 · Cited by 75
Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation
Saroja, S. R., Gorbachev, K., Julia, T., Goate, A. M., & Pereira, A. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108870119 · Cited by 75
p70 S6 Kinase and Tau in Alzheimer's Disease
Pei, J.-J., Björkdahl, C., Zhang, H., Zhou, X., & Winblad, B. G. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14405 · Cited by 75
Neuropathological Criteria for the Diagnosis of Alzheimer’s Disease
Markesbery, W. R. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00064-x · Cited by 75
Involvement of microtubule integrity in memory impairment caused by colchicine
Nakayama, T., & Sawada, T. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00634-7 · Cited by 75
The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age
Fonseca, M. I., Head, E., Velázquez, P., Cotman, C. W., & Tenner, A. J. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7058 · Cited by 75
Neuroimaging insights into network-based neurodegeneration
Greicius, M. D., & Kimmel, D. L. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a26b3 · Cited by 76
Disruption of the cytoskeleton in Alzheimer's disease
Lee, V. M. ‐. (1995) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(95)80073-5 · Cited by 75
Hall, G. F., Yao, J., & Lee, G. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4733 · Cited by 76
Chapter 21 Neurofibrillary pathology of Alzheimer's disease and other tauopathies
Goedert, M. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64022-4 · Cited by 77
Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets
Zádori, D., Veres, G., Szalárdy, L., Klivènyi, P., Toldi, J., & Vécsei, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132621 · Cited by 76
Poon, C. H., Wang, Y., Fung, M., Zhang, C., & Lim, L. W. (2020) · Aging and Disease · doi:10.14336/ad.2019.1026 · Cited by 76
Park, Y., Nirajan, K. C., Paneque, A., & Cole, P. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126295 · Cited by 78
Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease
Hellström‐Lindahl, E., Viitanen, M. H., & Marutle, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.03.007 · Cited by 78
Zhu, L., Wang, S. H., Ling, Z.-Q., Wang, D. L., & Wang, J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00136.x · Cited by 74
Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis
Schneider, A., Araújo, G. W., Trajković, K., Herrmann, M. M., Merkler, D., Mandelkow, E., Weissert, R., & Simons, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409954200 · Cited by 72
Mercken, M. H., Grynspan, F., & Nixon, R. A. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00590-6 · Cited by 74
The role of GSK3 in Alzheimer disease
Hernández, F., de Barreda, E. G., Fuster-Matanzo, A., Goñi‐Oliver, P., Lucas, J. J., & Ávila, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.05.017 · Cited by 73
Mondragón‐Rodríguez, S., Perry, G. L., Zhu, X., & Boehm, J. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/630182 · Cited by 74
Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model
Orejana, L., Barros-Miñones, L., Jordán, J., Puerta, E., & Aguirre, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.018 · Cited by 73
Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias
Nasrallah, I. M., & Wolk, D. A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.141416 · Cited by 76
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
